Plasma cell-free DNA as a monitoring tool for high-risk pregnancies associated with antiphospholipid syndrome

• Published in: Thrombosis research Vol. 241; p. 109108
• Main Authors: Cepeda, Julieta, Racca, M. Emilia, Cardozo, M. Alejandra, Gaydou, Luisa, Muñoz-de-Toro, Mónica, Milesi, M. Mercedes, Varayoud, Jorgelina, Rossetti, M. Florencia, Ramos, Jorge G.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.09.2024
• Subjects: Antiphospholipid syndrome; Cell-free DNA; Pregnancy; APS; NS; ROC; aCL; EDTA; ACTB; aβ2GPI; AUC; DS; Pregnancy; FGR; LMWH; 2ndT; LA; PE; cfDNA; 3rdT; Cell-free DNA; 1stT; aPLs; HC; NET; Antiphospholipid syndrome; BMI
• ISSN: 0049-3848; 1879-2472; 1879-2472
• DOI: 10.1016/j.thromres.2024.109108

Despite thromboprophylaxis, women with antiphospholipid syndrome (APS) face high-risk pregnancies due to proinflammatory and prothrombotic states. This highlights the need for new monitoring and prognostic tools. Recent insights into the pathophysiological role of neutrophil activation and extracellular trap (NET) formation in this syndrome led to the exploration of plasma cell-free DNA (cfDNA), a derivative of NETosis, as a promising biomarker. cfDNA was isolated and quantified from plasma samples of healthy pregnant women (control group, HC) and women with APS (APS group). We assessed the physiological variability of cfDNA across the three trimesters in HC. Levels of cfDNA were compared between APS and HC by gestational trimester. ROC curve analysis was performed to evaluate the efficacy of cfDNA levels for classifying APS patients. Furthermore, cfDNA levels in pregnant women with APS with obstetric complications were compared to those from uncomplicated pregnancies. Among HC, cfDNA significantly increased in the third trimester compared to the first and second. Elevated cfDNA levels in APS compared to HC were observed in the first and second trimesters. First-trimester cfDNA levels demonstrated the highest classification ability to discriminate between APS and HC patients (AUC: 0.906). Among APS, those with complicated pregnancies (fetal growth restriction, preeclampsia, placenta accreta) exhibited significantly elevated cfDNA levels in the second trimester. Elevated levels of cfDNA in pregnant women with APS, particularly among those with obstetric complications, supports further investigation into the potential of cfDNA as a valuable tool in the obstetric management of women with APS. [Display omitted] •Women with APS face high-risk pregnancies and new monitoring tools are imperative.•cfDNA level is increased in pregnant women with APS.•Among APS pregnant women, cfDNA is higher in those with obstetric complications.•cfDNA is a potential biomarker for monitoring pregnant women with APS.